Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines Abstract #1590

Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki67<10%, low tumor burden, no symptoms, and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group-3, symptomatic patients or with Ki67>10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed
Aim(s): This study aimed to determine distribution, patient characteristics, and outcome among these 3 groups
Materials and methods: Patients with mP-NET from 2004 to 2016 were categorized into the 3 groups. Prognosis was calculated using the Kaplan-Meier method. All treatments were recorded and consistency with ENETS guidelines was explored
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Margaux Foulfoin
Keywords: pancreas, metastasis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#110 Slug represents an important regulator of E-cadherin expression in neuroendocrine tumor cells of the pancreas
Introduction: Neuroendocrine tumors of the pancreas form an inhomogenous group of epithelial neoplasms. They differ from other types of pancreatic cancers by showing an extended survival of patients, which is due to a mostly slow proliferation rate of the tumor. However, some of these neuroendocrine tumors are characterized by an early onset of metastases, which cannot be predicted by any available method. The epithelial to mesenchymal transition (EMT) represents a central part of cell migration and metastasis. During EMT, cells loosen their cellular contacts, leave the tissue, and become migrating single cells. One of the integral compounds of cell adhesion represents the E-cadherin adhesion module, which contains mostly E-cadherin and several catenins. A loss of this adhesion module is associated with tumor progression, migration and metastasis in many types of cancer.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Alexander König
#2040 Hepatic Tumor Burden Can Be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)
Introduction: The main tumor burden of patients with neuroendocrine tumor liver metastasis is comprised by hepatic lesions.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Yiming Liu
Authors: Liu Y, Wang Y, Lian F, Shen L, ...
#717 A Pancreatic Metastasis from Carcinoid Midgut Tumor
Introduction: Metastatic lesions to the pancreas are rare.
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: professor Claudio Pasquali
#2041 Hepatic Tumor Burden Can be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)
Introduction: The main tumor burden of patients with neuroendocrine tumor liver metastasis is comprised by hepatic lesions.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Yiming Liu
Authors: Liu Y, Wang Y, Lian F, Shen L, ...
#1539 Slit-Robo Signaling Links to Ras Activity to Suppress Metastasis and Is Associated with Time-to-Progression in Pancreatic Neuroendocrine Tumors
Introduction: mRNA signatures of distinct metastatic phenotypes of pancreatic NETs (pNETs) exhibit differences in several components of the Slit-Robo axon guidance system.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. med. Christian Fischer